YELESWARAM KRISHNASWAMY (Chief Development Officer) sold 20.4% of their position (50.16K shares) of RAPPORT THERAPEUTICS, INC. on the open market
Open‑market sale worth $2.53M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 8/26/2026ACC: 0001193125-26-368244
Officer· Chief Development Officer
Since Feb 2026
-50.16K
Net shares
Net seller
$2.53M
Total sold
3
Open market trades
0B · 3S
3
Total transactions
50.16K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−13.16K
Price / share
$50.00
Trade value
$657.98K
% of position
5.3%
8/24/2026
246.02K→232.86K
Common Stock
Direct
Shares
−20.80K
Price / share
$50.31
Trade value
$1.05M
% of position
8.9%
8/25/2026
232.86K→212.06K
Common Stock
Direct
Shares
−16.20K
Price / share
$51.06
Trade value
$827.18K
% of position
7.6%
8/25/2026
212.06K→195.86K
Total
Net shares
−50.16K
Net value
-$2.53M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/24/2026 | S · Sale | −13.16K | $50.00 | $657.98K | 5.3% | 246.02K | 232.86K |
| Common Stock Direct | 8/25/2026 | S · Sale | −20.80K | $50.31 | $1.05M | 8.9% | 232.86K | 212.06K |
| Common Stock Direct | 8/25/2026 | S · Sale | −16.20K | $51.06 | $827.18K | 7.6% | 212.06K | 195.86K |
| Total | −50.16K | -$2.53M | ||||||
Derivative Transactions0
No derivative transactions reported